Search

Displaying results 1951 - 1960 of 4335 in total
  1. Drug

    Dalteparin

    go.drugbank.com/drugs/DB06779
    ApprovedInvestigational

    Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains ...

  2. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [L51139] Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as [ivosidenib] and [enasidenib].

  3. Drug

    Etoposide

    go.drugbank.com/drugs/DB00773
    ApprovedInvestigational

    A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair b...

  4. Drug

    Laronidase

    go.drugbank.com/drugs/DB00090
    ApprovedInvestigational

    The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase.

  5. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [A274501, L54101] Remibrutinib has also been investigated in other inflammatory conditions,[A274511] such as autoimmune encephalomyelitis [A274501] and Sjögren's syndrome.[A274521]

  6. Drug

    Molybdenum

    go.drugbank.com/drugs/DB11137
    ApprovedInvestigational

    As it is not a naturally occuring free metal on Earth, molybdenum is found only in various oxidation states in minerals. … When complexed with Technetium Tc 99m, molybdenum is used as a radiopharmaceutical agent in diagonistic procedures.

  7. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

  8. Drug

    Hydrocortamate

    go.drugbank.com/drugs/DB00769
    Approved

    Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised ...

  9. Drug

    Vutrisiran

    go.drugbank.com/drugs/DB16699
    ApprovedInvestigational

    [L34490,L42065] Vutrisiran is commercially available as a conjugate of N-acetylgalactosamine (GalNAc), a residue that enables the delivery of siRNA to hepatocytes.

  10. Drug

    Cabergoline

    go.drugbank.com/drugs/DB00248
    ApprovedInvestigational

    Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.